Thermo Fisher to Acquire Sanofi's Ridgefield Sterile Manufacturing Site

Thermo Fisher Scientific has reached an agreement to acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, New Jersey. The site, specializing in fill‑finish and packaging of aseptic injectable medications, currently employs over 200 staff who will transfer to Thermo Fisher upon deal completion. The acquisition is expected to close in late 2025 and aligns with both companies’ strategic initiatives to bolster U.S. pharmaceutical manufacturing.

Sanofi is ramping up investments in U.S. manufacturing and research, targeting at least $20 billion by 2030. Thermo Fisher, which is committing roughly $2 billion to enhance its domestic production capacity, views the Ridgefield location as a key asset. CEO Marc Casper highlighted that the acquisition strengthens Thermo Fisher’s ability to support pharmaceutical and biotech customers requiring critical sterile manufacturing capacity, while reinforcing its partnership with Sanofi.

This move aligns with broader industry trends aimed at on‑shoring production amid global supply chain pressures, including tariff concerns. The deal is expected to boost employment at the facility and enhance continuity of sterile drug production for both Sanofi’s therapies and other clients seeking U.S.-based capacity.